Recently, published in the International Journal of The Journal of Nuclear Medicine on a research paper, the researchers from the University of Stellenbosch, said the use of a customized nuclear medicine therapy or as a novel cancer therapy more effectively treatment of cancer patients, the treatment process is also beneficial because some patients benefit from targeted radiation sickness.

The use of radiopharmaceuticals in nuclear medicine – targeted therapy of radioactive compounds may have potential for the treatment of cancer, especially those cancer has spread to lymph nodes and secondary organ cancer patients, which is difficult to use a single cancer cell proliferation formulations for treatment, because each of the different target cell receptors in terms of effects of the drug will produce a significant difference.

In this study, researchers used four fluorescent conjugated monoclonal antibody cocktail for targeting breast cancer cells, the amount of antibody binding on every cancer can be determined by cell count; then researchers developed a new algorithm designed to carry the radionuclide and special active antibody, and calculating the absorbed dose per cell, the cell performance residual mixture which simulates the study of cancer cells when exposed to a different antibody when the coupling agent, this simulation process can be accomplished three particle emitter.

Said Dr. Roger Howell, our technology can be applied to radiation therapy to the molecular level from the tumor cell level of cancer treatment, the current concept is not limited to the treatment of cancer, but more widely used for other diseases treatment, then the use of a mixed preparation of radiopharmaceuticals perhaps meet this requirement; in special cases, the effect of mixing radiopharmaceutical formulation is significantly better than the effect of a single antibody therapy, Human CXC-chemokine ligand 16 ELISA Kithttp://www.cusabio.com/ELISA_Kit-73491/ targeted therapies might ? be customized radiolabeled antibody cocktail improved, binding and activity is dependent on the radioactive antibodies, mixed formulations can provide sustained effect tumor cell killing.

Finally, the researchers said, this new method is very good, which includes almost all of the mode of action of the drug in the body of the patient, and the design goal of any therapy is that patients in the planning stage and will not accept the test injection of radiopharmaceuticals, and in the treatment phase can be injection radiopharmaceuticals, so special customized for the individual pharmaceutical preparations may be able to effectively treat an individual disease.